Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for renal denervation (RDN) for uncontrolled hypertension, with an effective date of May 15, 2026. Here's what billing teams need to know before that date.
Renal denervation billing has been a moving target since the FDA cleared the Recor Medical Paradise system in 2023. CMS has now issued a modified coverage policy that billing teams, interventional cardiology practices, and hospital outpatient departments need to review carefully. The policy does not list specific CPT or HCPCS codes in the data available at publication — we'll cover what that means for your charge capture below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Renal Denervation (RDN) for Uncontrolled Hypertension |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Interventional Cardiology, Nephrology, Vascular Surgery, Hospital Outpatient |
| Key Action | Audit your charge capture and prior authorization workflows for RDN procedures before May 15, 2026 |
CMS Renal Denervation Coverage Criteria and Medical Necessity Requirements 2026
The central question for any RDN claim is whether Medicare considers the procedure medically necessary for a specific patient. That question got more complicated — and more consequential — with this May 2026 modification.
Renal denervation is a catheter-based procedure. It delivers ultrasound or radiofrequency energy to the renal arteries to disrupt sympathetic nerve activity. The goal is to lower blood pressure in patients whose hypertension remains uncontrolled despite medication.
CMS has historically approached RDN with caution. The procedure spent years in clinical trial status before the FDA cleared the Recor Medical Paradise ultrasound-based system in November 2023. That clearance triggered renewed pressure on CMS to define a Medicare coverage policy — and this May 2026 update is the agency's latest response to that pressure.
Medical necessity criteria for RDN under Medicare generally center on:
| # | Covered Indication |
|---|---|
| 1 | A diagnosis of uncontrolled hypertension, defined as elevated blood pressure despite adherence to a stable antihypertensive medication regimen |
| 2 | Documentation of medication adherence — this is critical. CMS and Medicare Administrative Contractors want to see that hypertension is truly treatment-resistant, not undertreated |
| 3 | Evidence that secondary causes of hypertension have been evaluated and ruled out |
| 4 | Appropriate patient selection as defined by the FDA-cleared device's indication |
The coverage policy ties medical necessity tightly to the evidence base from clinical trials. CMS scrutinizes whether a procedure has Level I evidence behind it. For RDN, the SPYRAL HTN and RADIANCE trial programs are the primary evidence sources CMS reviewers reference.
If your practice is billing for RDN under Medicare, your documentation needs to tell a clear story: this patient has true treatment-resistant hypertension, has been adherent to medications, and has been properly evaluated before the procedure. Thin documentation is the fastest path to a claim denial.
Prior authorization requirements for RDN under Medicare vary by Medicare Administrative Contractor. CMS does not uniformly mandate prior authorization for all covered procedures across all MACs, but given the cost and clinical complexity of RDN, many MACs have issued or are expected to issue local coverage determination requirements. Check with your MAC before May 15, 2026 — do not assume national policy is the only gate you have to clear.
CMS Renal Denervation Exclusions and Non-Covered Indications
CMS has been explicit that RDN is not a blanket treatment for all hypertension. Several patient populations and clinical scenarios fall outside covered indications.
Non-covered indications include:
| # | Excluded Procedure |
|---|---|
| 1 | Hypertension that is not truly uncontrolled (i.e., elevated readings that reflect white coat hypertension, poor measurement technique, or non-adherence rather than treatment failure) |
| 2 | Secondary hypertension with an identifiable, treatable cause — such as primary aldosteronism, renal artery stenosis, or obstructive sleep apnea — that has not been addressed |
| 3 | RDN performed outside of an FDA-cleared device indication |
| 4 | Repeat RDN procedures without documented evidence of initial response and clinical justification for retreatment |
The experimental designation is the real financial risk here. If a MAC determines that a specific RDN procedure or device falls outside the cleared indication, the claim won't just get denied — it may trigger medical necessity review on related claims. That's the kind of downstream exposure that warrants a conversation with your compliance officer before you build RDN into your standard charge capture.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Uncontrolled hypertension with documented medication adherence, secondary causes ruled out, using FDA-cleared device | Covered (subject to medical necessity documentation) | Codes not specified in available policy data | Prior auth requirements vary by MAC; verify before billing |
| Hypertension with identifiable secondary cause not yet treated | Not Covered | — | Must treat underlying cause first |
| White coat or non-adherence-related elevated BP | Not Covered | — | Does not meet medical necessity threshold |
| RDN with non-FDA-cleared device or outside cleared indication | Experimental / Not Covered | — | Coverage denial expected; legal and compliance review recommended |
| Repeat RDN without documented clinical justification | Not Covered | — | Retreatment criteria not established in current policy |
CMS Renal Denervation Billing Guidelines and Action Items 2026
Renal denervation billing under Medicare is not a set-it-and-forget-it charge capture situation. The May 15, 2026 effective date is your deadline to get your workflow right.
| # | Action Item |
|---|---|
| 1 | Contact your MAC now — before May 15, 2026. Ask specifically whether your MAC has issued or plans to issue a local coverage determination for RDN. National CMS policy sets the floor; MACs can impose additional requirements. Some MACs may require prior authorization even if CMS policy doesn't mandate it universally. |
| 2 | Audit your documentation templates for RDN cases. Before May 15, 2026, your clinical documentation should capture: confirmed uncontrolled hypertension diagnosis, documented medication regimen and adherence, evaluation for secondary causes with findings, device used (and confirmation it's FDA-cleared), and treating physician attestation of medical necessity. Missing any of these elements is a direct path to a claim denial. |
| 3 | Verify which CPT codes your practice is using for RDN. The available policy data does not list specific CPT or HCPCS codes. This is a gap you must close with your MAC or billing consultant before the effective date. Using an unlisted procedure code without confirming the correct billing code creates audit risk and delays reimbursement. |
| 4 | Build a prior authorization workflow specifically for RDN. Even if your MAC doesn't require prior auth today, the cost and complexity of this procedure make it a high-scrutiny claim. A proactive prior authorization process protects your reimbursement and creates a documented paper trail if coverage is challenged. |
| 5 | Train your coding team on the medical necessity distinction. The difference between covered and non-covered RDN is almost entirely in the documentation — not the procedure itself. Your coders need to know what to look for before a claim goes out the door. A claim that goes out with incomplete medical necessity documentation won't come back with a simple fix. |
| 6 | Flag existing RDN cases in your AR for review. If your practice has billed RDN under Medicare in the past 12 months, review those claims against the updated coverage policy criteria. If the documentation is thin on medication adherence or secondary cause evaluation, consider whether those claims carry audit exposure. |
If you're not sure how this modified coverage policy applies to your patient mix or payer contracts, talk to your compliance officer and a billing consultant before May 15, 2026. The combination of high procedure cost, evolving coverage criteria, and MAC-level variation makes this a situation where getting expert eyes on your workflow pays for itself.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Renal Denervation Under CMS Policy
Available Code Data
The CMS policy document available at publication does not list specific CPT, HCPCS Level II, or ICD-10-CM codes for renal denervation. This is not unusual for a modified national policy — code-level detail often lives in the associated LCD or MAC-specific billing guidelines rather than the national document.
This means your billing team has a concrete task: get the correct codes directly from your MAC.
Do not attempt to bill RDN using codes derived from similar procedures (such as renal artery stenting or catheter ablation codes) without explicit guidance from your MAC or a qualified billing consultant. Miscoded RDN claims are difficult to appeal and may trigger broader claim review.
What to Ask Your MAC
When you contact your MAC, ask specifically:
- What CPT or HCPCS code(s) does your jurisdiction accept for renal denervation procedures using FDA-cleared ultrasound-based or radiofrequency-based systems?
- Is there a specific ICD-10-CM code combination required to support medical necessity for RDN claims?
- Has your MAC issued — or does it plan to issue — an LCD for RDN before May 15, 2026?
Document the responses you receive, including the date, the MAC representative's name, and any written confirmation. That documentation is your first line of defense in an audit.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.